Literature DB >> 3341991

Effect of metoprolol on diet-induced atherosclerosis in rabbits.

A M Ostlund-Lindqvist1, P Lindqvist, J Bräutigam, G Olsson, G Bondjers, C Nordborg.   

Abstract

The effect of metoprolol, a beta 1-blocker, on atherogenesis was evaluated in rabbits fed a diet supplemented with 0.25% cholesterol and 3% coconut oil for 21 weeks. After 7 weeks on the diet, the rabbits were randomly divided into treated (n = 22) and untreated (n = 22) groups. Treated animals received metoprolol subcutaneously by an osmotic pump for 14 weeks, resulting in a plasma level of 774 +/- 69 nM during the investigation. Plasma concentrations of cholesterol, triglycerides, and phospholipids did not differ between the two groups. Nor were there any significant differences between the two groups in plasma concentrations of apolipoprotein A-I, apolipoprotein B, apolipoprotein C-III, and apolipoprotein E measured by electroimmunoassay. At the end of the study, the aortas were cut into three portions and the extent of atherosclerosis was determined by morphometry. The group that had received metoprolol had significantly (p less than 0.015) less atherosclerosis in the aorta (ascending plus arch 37.8 +/- 6.8%, thoracic 32.9 +/- 6.1%, abdominal 19.8 +/- 6.1% of total intimal area; mean +/- SEM) than the controls (ascending plus arch 54.9 +/- 7.1%, thoracic 48.0 +/- 6.2%, abdominal 25.9 +/- 5.5%).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3341991     DOI: 10.1161/01.atv.8.1.40

Source DB:  PubMed          Journal:  Arteriosclerosis        ISSN: 0276-5047


  9 in total

1.  Effects of beta-blockers on HMG CoA reductase and LDL receptor activity in cultured human skin fibroblasts.

Authors:  H Yoshida; M Suzukawa; T Ishikawa; H Shige; E Nishio; H Hosoai; M Ayaori; H Nakamura
Journal:  Cardiovasc Drugs Ther       Date:  1996-03       Impact factor: 3.727

Review 2.  Modification of atherosclerosis by agents that do not lower cholesterol.

Authors:  J G Cleland; D M Krikler
Journal:  Br Heart J       Date:  1993-01

3.  The QT interval is associated with incident cardiovascular events: the MESA study.

Authors:  Roy Beinart; Yiyi Zhang; João A C Lima; David A Bluemke; Elsayed Z Soliman; Susan R Heckbert; Wendy S Post; Eliseo Guallar; Saman Nazarian
Journal:  J Am Coll Cardiol       Date:  2014-11-10       Impact factor: 24.094

4.  Clinical and angiographic variables affecting the progression of coronary artery disease as determined by quantitative angiography.

Authors:  A Joseph; J D Talley; A Shih; T Crum; R Vogel; J Kupersmith
Journal:  Int J Card Imaging       Date:  1994-09

Review 5.  Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease.

Authors:  G L Plosker; S P Clissold
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

Review 6.  Controlled release metoprolol. Clinical pharmacokinetic and therapeutic implications.

Authors:  M J Kendall; S R Maxwell; A Sandberg; G Westergren
Journal:  Clin Pharmacokinet       Date:  1991-11       Impact factor: 6.447

7.  Inhibition of platelet accumulation by beta 1-adrenoceptor blockade in the thoracic aorta of rabbits subjected to experimental sympathetic activation.

Authors:  K Pettersson; H Björk
Journal:  Cardiovasc Drugs Ther       Date:  1992-10       Impact factor: 3.727

Review 8.  Use of beta-adrenoceptor blockers in patients with congestive heart failure.

Authors:  V Panfilov; I Wahlqvist; G Olsson
Journal:  Cardiovasc Drugs Ther       Date:  1995-04       Impact factor: 3.727

9.  Metoprolol reduces proinflammatory cytokines and atherosclerosis in ApoE-/- mice.

Authors:  Marcus A Ulleryd; Evelina Bernberg; Li Jin Yang; Göran M L Bergström; Maria E Johansson
Journal:  Biomed Res Int       Date:  2014-07-08       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.